 Ocugen Inc. stock OCGN, 0.78 rallied 16 in premarket trade Monday, after the biopharma company announced positive results in a trial of its COVID vaccine Covaxin. The Phase 23 trial involved 491 U.S. adult participants who receive two doses of Covaxin or placebo 28 days apart. 